Comparison of efficacy and safety between rifapentine and rifampicin in the treatment of tuberculosis
10.3760/cma.j.issn.1008-6706.2019.17.009
- VernacularTitle: 利福喷丁与利福平治疗肺结核的疗效和安全性比较
- Author:
Mingchong XU
1
;
Keke XU
;
Zhiming SUN
Author Information
1. Department of Tuberculosis, the Traditional Chinese Medicine Hospital of Cixi, Cixi, Zhejiang 315300, China
- Publication Type:Journal Article
- Keywords:
Tuberculosis, pulmonary;
Comparative effectiveness research;
Safety;
Rifampicin;
Rifampicin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(17):2083-2086
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe and compare the clinical efficacy and safety of rifapentine and rifampicin in the treatment of tuberculosis.
Methods:From January 2015 to January 2018, 398 tuberculosis patients admitted to Tuberculosis Clinic of the Traditional Chinese Medicine Hospital of Cixi were selected and randomly divided into observation group and control group by complete Random Distribution Method, with 199 cases in each group.The two groups were given basic treatments such as isoniazid, pyrazinamide and ethambutol.On this basis, patients in the control group were treated with rifampicin, and the observation group was treated with rifapentine.The treatment time of both two groups was 6 months.The sputum bacterial conversion rate, lesion absorption rate and cavity closure rate were observed, and the clinical treatment effect and adverse reactions were compared between the two groups.
Results:The sputum bacteria conversion rate (77.89%), lesion absorption rate (71.86%) and cavity closure rate (74.87%) in the control group were significantly lower than those in the the observation group(96.98%, 91.96%, 95.98%) (χ2=31.03, 27.13, 35.60, all P<0.01). The total effective rate of the observation group was 93.97%, which was higher than 75.88% of the control group, and the difference was statistically significant (χ2=38.37, P<0.01). The incidence rate of adverse reactions in the observation group was 12.56%, which was significantly lower than 29.56% in the control group, the difference was statistically significant (χ2=17.59, P<0.01).
Conclusion:Compared with rifampicin, rifapentine is effective in treating pulmonary tuberculosis patients with high safety and effective improvement of clinical symptoms, which is worthy of further application.
